Dataset Information

C1q binding to surface-bound IgG is stabilized by C1r2s2 proteases.

ABSTRACT: Complement is an important effector mechanism for antibody-mediated clearance of infections and tumor cells. Upon binding to target cells, the antibody's constant (Fc) domain recruits complement component C1 to initiate a proteolytic cascade that generates lytic pores and stimulates phagocytosis. The C1 complex (C1qr2s2) consists of the large recognition protein C1q and a heterotetramer of proteases C1r and C1s (C1r2s2). While interactions between C1 and IgG-Fc are believed to be mediated by the globular heads of C1q, we here find that C1r2s2 proteases affect the capacity of C1q to form an avid complex with surface-bound IgG molecules (on various 2,4-dinitrophenol [DNP]-coated surfaces and pathogenic Staphylococcus aureus). The extent to which C1r2s2 contributes to C1q-IgG stability strongly differs between human IgG subclasses. Using antibody engineering of monoclonal IgG, we reveal that hexamer-enhancing mutations improve C1q-IgG stability, both in the absence and presence of C1r2s2 In addition, hexamer-enhanced IgGs targeting S. aureus mediate improved complement-dependent phagocytosis by human neutrophils. Altogether, these molecular insights into complement binding to surface-bound IgGs could be important for optimal design of antibody therapies.

SUBMITTER: Zwarthoff SA

PROVIDER: S-EPMC8256010 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

C1q binding to surface-bound IgG is stabilized by C1r2s2 proteases.

Zwarthoff Seline A SA Widmer Kevin K Kuipers Annemarie A Strasser Jürgen J Ruyken Maartje M Aerts Piet C PC de Haas Carla J C CJC Ugurlar Deniz D den Boer Maurits A MA Vidarsson Gestur G van Strijp Jos A G JAG Gros Piet P Parren Paul W H I PWHI van Kessel Kok P M KPM Preiner Johannes J Beurskens Frank J FJ Schuurman Janine J Ricklin Daniel D Rooijakkers Suzan H M SHM

Proceedings of the National Academy of Sciences of the United States of America 20210601 26

Complement is an important effector mechanism for antibody-mediated clearance of infections and tumor cells. Upon binding to target cells, the antibody's constant (Fc) domain recruits complement component C1 to initiate a proteolytic cascade that generates lytic pores and stimulates phagocytosis. The C1 complex (C1qr2s2) consists of the large recognition protein C1q and a heterotetramer of proteases C1r and C1s (C1r2s2). While interactions between C1 a ...[more]

PMID: 34155115

Similar Datasets

Project description:Monoclonal antibodies directed against the CD20 surface antigen on B cells are widely used in the therapy of B cell malignancies. Upon administration, the antibodies bind to CD20 expressing B cells and induce their depletion via cell- and complement-dependent cytotoxicity or by induction of direct cell killing. The three antibodies currently most often used in the clinic are Rituximab (RTX), Ofatumumab (OFA) and Obinutuzumab (OBI). Even though these antibodies are all of the human IgG1 subclass, they have previously been described to vary considerably in the effector functions involved in therapeutic B cell depletion, especially in regards to complement activation. Whereas OFA is known to strongly induce complement-dependent cytotoxicity, OBI is described to be far less efficient. In contrast, the role of complement in RTX-induced B cell depletion is still under debate. Some of this dissent might come from the use of different in vitro systems for characterization of antibody effector functions. We therefore set out to systematically compare antibody as well as C1q binding and complement-activation by RTX, OFA and OBI on human B cell lines that differ in expression levels of CD20 and complement-regulatory proteins as well as human primary B cells. Applying real-time interaction analysis, we show that the overall strength of C1q binding to live target cells coated with antibodies positively correlated with the degree of bivalent binding for the antibodies to CD20. Kinetic analysis revealed that C1q exhibits two binding modes with distinct affinities and binding stabilities, with exact numbers varying both between antibodies and cell lines. Furthermore, complement-dependent cell killing by RTX and OBI was highly cell-line dependent, whereas the superior complement-dependent cytotoxicity by OFA was independent of the target B cells. All three antibodies were able to initiate deposition of C3b on the B cell surface, although to varying extent. This suggests that complement activation occurs but might not necessarily lead to induction of complement-dependent cytotoxicity. This activation could, however, initiate complement-dependent phagocytosis as an alternative mechanism of therapeutic B cell depletion.

Dataset Information

C1q binding to surface-bound IgG is stabilized by C1r2s2 proteases.

Publications

C1q binding to surface-bound IgG is stabilized by C1r<sub>2</sub>s<sub>2</sub> proteases.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

C1q binding to surface-bound IgG is stabilized by C1r2s2 proteases.

Publications

C1q binding to surface-bound IgG is stabilized by C1r&lt;sub&gt;2&lt;/sub&gt;s&lt;sub&gt;2&lt;/sub&gt; proteases.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

C1q binding to surface-bound IgG is stabilized by C1r<sub>2</sub>s<sub>2</sub> proteases.